Drug Profile
ACER 003
Alternative Names: ACER-003Latest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Acer Therapeutics
- Class Anti-inflammatories; Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
- Mechanism of Action Antioxidants; Free radical inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Systemic scleroderma
Most Recent Events
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
- 28 Jun 2019 No recent reports of development identified for clinical-Phase-Unknown development in Systemic-scleroderma in USA (Parenteral)
- 18 May 2016 Clinical trials in Systemic scleroderma in USA (Parenteral)